{"name":"EQRx International, Inc.","slug":"eqrx-international-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxOSmJHRDRiUFluS3FDc2NLZ18yNng1TnNNaXFNODJ1X3ctSG5FZHBtRUczT08xMGxCQnpUVUZfOFJlTkRxLWE2dkJhOUVmTlczU2x6bHQxRk1fRVRER0xRNXpFcHY0eUlaR0p0aEZxSmxuZ2ZOMlhrRWtEdXYtWk5rLTNXc3dfSDF5ZTVhd2NPUUtQbFRpcmpxU09xQjUyWmh5?oc=5","date":"2025-06-24","type":"pipeline","source":"BioWorld News","summary":"Revmed goes global with $2B in capital for RAS(ON) inhibitors - BioWorld News","headline":"Revmed goes global with $2B in capital for RAS(ON) inhibitors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE5qaVBMSHRzZXhKNGdvdG16TVdDM24wajJXVEhwS2dHTEttV21BMWx4WV95WXZYYkxucmhpd1cxZDFTeDhidks4OTIzWnBoY0xtYnZ6RzY4U3JfNXJKbkY1T2dpeHlHc2E4RUdsbmlIYnpXNzhQR2UtMmtLN1dnZDA?oc=5","date":"2023-10-05","type":"deal","source":"Fierce Biotech","summary":"From $4.2B deal to a desperate search for buyers: How EQRx's low-cost drug dream unraveled - Fierce Biotech","headline":"From $4.2B deal to a desperate search for buyers: How EQRx's low-cost drug dream unraveled","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxOemFuVWctRGdoNzFtRUd4aFRLTTRwWmdRWk90bHo3dUQ4RWZLbWFlTkJoUFEtMlhsWnpweTEzOTl3djdkaWRtOENyMkpseU5uZHpUdFpEbWJCTHJuT0ozdHJqSWRlRHJRNWdMWVdHck42Ql9CanM1ZV81VXF1X1BEaGJ3?oc=5","date":"2022-11-10","type":"pipeline","source":"BioPharma Dive","summary":"EQRx redraws ‘radical’ drug pricing plans for first two drugs - BioPharma Dive","headline":"EQRx redraws ‘radical’ drug pricing plans for first two drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxNeTdhbE5jYkluNDVnVTRVNDdsUHlxNWZUaWZFRWtPU0xuTFhiQllldklyS2xVLTZxUUZlMk1lQnRrejNVcnViQUlncVBHN2hNaGRaOEpYWi03RmZROTlNMGQ3OXRoR0hQUHRZTy01bkdJaWkyWkF0c2YtX0dabk56Q3djWVo3MnhnWVBvV0NVZHFiSXFyMkxySnV1cGdwYWp0?oc=5","date":"2022-08-11","type":"trial","source":"BioPharma Dive","summary":"EQRx, in bid to compete, takes on AstraZeneca’s top seller in head-to-head trial - BioPharma Dive","headline":"EQRx, in bid to compete, takes on AstraZeneca’s top seller in head-to-head trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxNY2RRUlhfZGlvZnItLWZHc3k1UWhNY0xSblIyVF83U0RtSWliYmFPT0VtaGVuY3JrUHdJUTROTVJhR2xEblp6N2llajRJZVhxVGlaUGl2Q1lONGpaVmtwRTJnbHdySFllSDVRamZZa0w1TmtJNnBJOW5ZWXI3RW1qelFqMGRyX2hxQ1pqb1FYM2Rjd1NaN2t3Vkg5YkhRQ3k2akQtZnZ4YjZRbEtNYjBHOFdBM0tZYkRrMndVX2o0VlZTRE9MUmN3WmFiM3Rkai12N1hZN3ZVZDNXSkJWTVFad25mM1pVc2pTOGhhTmsyVjFSSHNXemc2SlljRUthVUxjSWNzcHJibmM?oc=5","date":"2022-07-05","type":"deal","source":"Business Wire","summary":"Aurigene Discovery Technologies Limited Announces Drug Discovery, Development and Commercialization Partnership with EQRx - Business Wire","headline":"Aurigene Discovery Technologies Limited Announces Drug Discovery, Development and Commercialization Partnership with EQR","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAJBVV95cUxNV3JOczlsWEdGcUlDcEdqbVYtdDV1VnlscWZXc3Bvc2VRdmVpM1puaGdWQTNxdDFoZmNHTG9oNndOVTU4X1gydUhBczhYaElCSmUyUTNHUTlHSV9IeF96VTJDdTVrb3h5UHNXTHY4VGhOVjVZTnNidG1oRzZKdHppdEpkUTJ1bGRhWG9QamdRR2VOX1ZtTHo3LS1QR0NGMEg3LV9mNkgwRnNnNzhMZHFOSVN0MzBSWDVOSUVsY0d1LXB3TE12eXZrR3JkUW5DdURJcFloT3ZMeW56d3BPSU1xNkl4SkdBU2hnOUFDSVZvMThGWTNmam40eW9OMXRSeDBhdjduZ2xNd3JZMWJZMmZQZENod1FMVGZJR0VsWmVmSFNVN3I2R0F2V0N1TXhBTDBucTcwWHJqRnBCUUd5V3dQY1dwbkU0NmEy?oc=5","date":"2021-11-22","type":"deal","source":"Abdul Latif Jameel","summary":"Abdul Latif Jameel Health & EQRx Announce Collaboration | Abdul Latif Jameel® - Abdul Latif Jameel","headline":"Abdul Latif Jameel Health & EQRx Announce Collaboration | Abdul Latif Jameel®","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}